Should tranexamic acid be used for acute upper gastrointestinal bleeding?

Tranexamic Acid for Upper Gastrointestinal Bleeding

Tranexamic acid should NOT be used routinely for acute upper gastrointestinal bleeding because high-quality evidence demonstrates no mortality benefit and an increased risk of thromboembolic events and seizures. 1

Guideline Recommendations

Current international guidelines do not recommend tranexamic acid for non-variceal upper GI bleeding. 2, 1 The 2019 International Consensus Group guidelines explicitly advise against its use, and the most recent evidence synthesis (2026) from major gastroenterology societies issues a strong recommendation against routine administration. 1

Historical Context and Evolution of Evidence

Older guidelines from 2002 noted that while tranexamic acid appeared to reduce the need for surgical intervention, it did not reduce ulcer rebleeding rates, and the evidence was deemed insufficient to recommend routine use. 2 These early meta-analyses were likely skewed by poor-quality trials conducted before modern endoscopic therapy and high-dose proton pump inhibitor use became standard. 1

Evidence from High-Quality Trials

The HALT-IT Trial (Definitive Evidence)

The HALT-IT trial, involving 12,009 participants (approximately 50% with suspected variceal bleeding), provides the highest-quality evidence and should guide current practice. 1 This trial demonstrated:

• No reduction in death from bleeding within 5 days 1
• Nearly two-fold increase in venous thromboembolic events, particularly among patients with liver disease or suspected variceal bleeding 1
• Increased seizure risk (risk ratio 1.73; 95% CI 1.03-2.93) 1, 3

The high-dose extended regimen used in HALT-IT (1 g IV loading dose over 10 minutes followed by continuous infusion) was directly linked to these observed harms. 1

Safety Concerns from FDA Drug Labeling

The FDA label for tranexamic acid highlights critical safety issues relevant to GI bleeding:

• Thromboembolic events including deep vein thrombosis, pulmonary embolism, and cerebral thrombosis have been reported in postmarketing surveillance 4
• Seizures may occur, particularly with higher doses 4
• Hypotension can occur with rapid IV administration 4
• The drug is contraindicated in patients with active intravascular clotting 4

Specific Clinical Scenarios

Non-Variceal Upper GI Bleeding

For peptic ulcer bleeding and other non-variceal sources, tranexamic acid is not recommended. 2, 1 Instead, prioritize:

• High-dose proton pump inhibitor therapy (80 mg IV bolus followed by 8 mg/hour infusion for 72 hours) following successful endoscopic therapy 2
• Early endoscopy within 24 hours with thermocoagulation, sclerosant injection, or clips for high-risk stigmata 2
• Restrictive transfusion strategy with hemoglobin threshold <80 g/L in patients without cardiovascular disease 2

Variceal Bleeding in Cirrhosis

The European Association for the Study of the Liver (EASL, 2022) issues a strong recommendation AGAINST tranexamic acid in patients with cirrhosis and active variceal bleeding. 1 The hypofibrinolytic state frequently present in critically ill cirrhotic patients may explain the lack of efficacy. 1

One notable exception: A 2024 single-center RCT (n=600) in patients with Child-Pugh B or C cirrhosis showed that tranexamic acid reduced failure to control bleeding by day 5 (6.3% vs 13.3%, p=0.006), particularly from post-EVL sites. 5 However, this study showed no mortality benefit, and this single trial contradicts the broader evidence base and guideline recommendations. 1, 5

For variceal bleeding, use:

• Vasoactive pharmacotherapy (octreotide, terlipressin, or somatostatin) 1
• Early endoscopic band ligation 2
• Antibiotic prophylaxis in cirrhotic patients 1

Lower Gastrointestinal Bleeding

The British Society of Gastroenterology (2019) advises that tranexamic acid use in acute lower GI bleeding should be limited to clinical trial settings only. 1 Recent meta-analyses show tranexamic acid is associated with increased mortality in lower GI bleeding (RR 1.67; 95% CI 1.44-1.93). 6

Conflicting Research Evidence

While some recent meta-analyses suggest potential benefits in reducing rebleeding rates, these findings must be interpreted cautiously:

• A 2025 meta-analysis showed reduced rebleeding (OR 0.64; 95% CI 0.45-0.91) but no mortality benefit and potential increased thromboembolic risk 7
• A 2023 single-center RCT (n=86) showed reduced rebleeding (25.6% vs 46.5%, p=0.043) but no mortality difference 8
• Multiple meta-analyses demonstrate that when restricted to low risk-of-bias studies only, the apparent mortality benefit disappears 1, 3

The key pitfall: Older studies showing benefit were conducted before modern endoscopic techniques and high-dose PPI therapy became standard, making them less applicable to current practice. 1

Clinical Bottom Line

Do not use tranexamic acid for acute upper GI bleeding. 1 The highest-quality evidence (HALT-IT trial) and current international guidelines converge on this recommendation. Focus instead on:

1. Immediate hemodynamic resuscitation 1
2. Early endoscopy with therapeutic intervention 2, 1
3. High-dose PPI therapy for non-variceal bleeding 2
4. Vasoactive drugs for variceal bleeding 1
5. Reversal of anticoagulation when appropriate 1

The potential for increased thromboembolic events and seizures, combined with lack of mortality benefit, makes tranexamic acid an inappropriate choice in this clinical setting. 1, 4